The coagulation markers market size is projected to be worth USD 1.21 billion in 2023. The market is likely to surpass USD 2.22 billion by 2033 at a CAGR of 6.3% during the forecast period. Growing surgical orthopedic procedures, such as venous thromboembolism (VTE), have resulted in a market increase.
According to several studies on preoperative risk assessment, the majority of patients undergoing major orthopedic surgery would be hypercoagulable. The use of coagulation markers in the screening of VTE has proven to be quite successful in detecting coagulation activation.
Other Drivers Propelling the Demand for Coagulation Markers include:
Challenges for Companies /Manufacturers in the Coagulation Markers Market:
Opportunities in the Coagulation Markers Industry:
Latest Trends in the Coagulation Markers Market:
Attributes | Details |
---|---|
Coagulation Markers Market Size (2023) | USD 1.21 billion |
Coagulation Markers Market Projected Size (2033) | USD 2.22 billion |
Value CAGR (2023 to 2033) | 6.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
From 2012 to 2022, the global coagulation markers market experienced a CAGR of 3.5%, reaching a market size of USD 1.21 billion in 2023. The increased frequency of coagulation diseases such as DVT, PE, and hemophilia has been a key driver for the coagulation markers industry. Because these illnesses are associated with anomalies in blood coagulation, there is a rising demand for coagulation indicators for diagnostic and monitoring purposes.
Increasing identification and diagnosis of coagulation abnormalities has resulted from increasing awareness of these illnesses, as well as enhanced diagnostic skills. Because healthcare personnel are now better trained to diagnose coagulation abnormalities, coagulation indicators are being used for diagnostic purposes. Early identification and management can enhance patient outcomes, propelling the industry forward.
Future Forecast for Coagulation Markers Industry:
Looking ahead, the global coagulation markers industry is expected to rise at a CAGR of 6.3% from 2023 to 2033. During the forecast period, the market size is expected to reach USD 2.22 billion.
The coagulation markers industry is expected to continue its growth trajectory from 2023 to 2033. Continuous technological improvements, such as the development of innovative assays, point-of-care testing devices, and high-throughput automated analyzers, will fuel market expansion. These developments will increase the sensitivity, accuracy, and efficiency of coagulation marker testing, resulting in improved diagnostic capabilities and simpler processes.
The rise of personalized medicine and tailored therapeutics will drive up demand for coagulation indicators. By analyzing coagulation indicators, healthcare practitioners may personalize treatment strategies based on an individual's unique coagulation profile, improving therapeutic results while reducing the risk of bleeding or thrombotic events.
Country | The United States |
---|---|
Market Size (USD billion) by End of Forecast Period (2033) | USD 731.3 million |
CAGR % 2023 to End of Forecast (2033) | 7.3% |
The coagulation markers industry in the United States is expected to reach a market value of USD 731.3 million by 2033, expanding at a CAGR of 7.3%. The United States continues to experience rapid growth in market due to increasing prevalence of coagulation disorders. The prevalence of coagulation diseases such as deep vein thrombosis (DVT), pulmonary embolism (PE), and other thrombotic illnesses has increased in the United States. As a result, there is a greater need for coagulation indicators for the early identification, diagnosis, and monitoring of these illnesses.
Country | The United Kingdom |
---|---|
Market Size (USD billion) by End of Forecast Period (2033) | USD 160.8 million |
CAGR % 2023 to End of Forecast (2033) | 9.4% |
The coagulation markers industry in the United Kingdom is expected to reach a market value of USD 160.8 million, expanding at a CAGR of 9.4% during the forecast period. The United Kingdom market is projected to experience growth owing to the rising aging population. The United Kingdom has an ageing population, with an increasing number of older people. Advanced age increases the risk of coagulation diseases such atrial fibrillation, venous thromboembolism, and stroke. Coagulation marker testing is becoming more popular as the population ages in order to determine the risk of thrombotic events and guide anticoagulant medication.
Country | China |
---|---|
Market Size (USD billion) by End of Forecast Period (2033) | USD 276.6 million |
CAGR % 2023 to End of Forecast (2033) | 9.0% |
The coagulation markers industry in China is anticipated to reach a market value of USD 276.6 million, moving at a CAGR of 9.0% during the forecast period. The coagulation markers industry in China is expected to grow prominently due to the increasing research and development. The long-term socioeconomic growth of China is being centered on scientific and technical innovation, which the Chinese government is promoting through financing, reform, and societal prestige. China's 14th five-year plan (2021-2025) is focused on pursuing innovation-driven growth and aims for research and development investment to expand by more than 7% annually over that time.
The top scientific magazine, Nature Index 2020 Annual Tables, reports that China's contribution to worldwide natural science research climbed by 15% in 2020. The country's favorable environment ensures that the advances in research production witnessed in previous years will continue.
Country | Japan |
---|---|
Market Size (USD billion) by End of Forecast Period (2033) | USD 127.3 million |
CAGR % 2023 to End of Forecast (2033) | 6.6% |
The coagulation markers industry in Japan is estimated to reach a market value of USD 127.3 million by 2033, thriving at a CAGR of 6.6%. The market in Japan is predicted to grow because of the growing demand for novel therapies. Ongoing research and development activities focusing on the development of novel coagulation markers, enhanced testing procedures, and customized assays for the Japanese population have aided market expansion. Collaborations among pharmaceutical firms, research institutes, and healthcare providers foster innovation and the development of enhanced coagulation marker testing.
Country | South Korea |
---|---|
Market Size (USD billion) by End of Forecast Period (2033) | USD 74.1 million |
CAGR % 2023 to End of Forecast (2033) | 5.9% |
The coagulation markers industry in South Korea is expected to reach a market value of USD 74.1 million, expanding at a CAGR of 5.9% during the forecast period. The market in South Korea is forecasted to witness growth due to the high healthcare expenditure. South Korea spends a lot on healthcare, and the investment in diagnostics and laboratory testing is growing. Coagulation marker tests are an essential aspect of diagnosing coagulation disorders. Coagulation markers market expansion is further aided by the availability of healthcare insurance coverage and reimbursement policies.
The D-dimer assay is expected to dominate the coagulation markers industry with a CAGR of 5.4% from 2023 to 2033. By-products of blood coagulation and breakdown, such as the D-dimer, can be detected via analysis of a blood sample. D-dimer is produced when a blood clot starts to dissolve. This explains why D-dimer test has a large market share.
When a doctor suspects that anything other than DVT or PE is the cause of the symptoms, D-dimer is extremely helpful. It is an efficient, non-invasive method to assist in ruling out irregular or excessive clotting as the underlying reason.
The plasma is expected to dominate the coagulation markers industry with a CAGR of 6.2% from 2022 to 2033.
Since plasma has a high quantity of fibrinogen, this method of detecting coagulation is frequently used. Along with other procoagulants like thrombin and factor X, fibrinogen is one of the main players in the process of blood clotting. The use of plasma as a specimen for coagulation tests is increasing as a result of this factor.
The ELISA is expected to dominate the coagulation markers industry with a CAGR of 5.4% from 2023 to 2033. The Human Coagulation Factor XII ELISA kit is intended for measuring coagulation factor XII levels in plasma. ELISA kits include recombinant monoclonal antibodies for specific and sensitive findings, as well as a single-wash technique that reduces test time to 90 minutes. The demand for ELISA kits is being driven by the shortened test time and effective outcomes.
Disseminated intravascular coagulation (DIC) is expected to dominate in the application segment with a CAGR of 6.7% from 2023 to 2033. Due to the rising incidence of cancer, it is projected that the market for diffused intravascular coagulation (DIC) would expand quickly over the forecast period. By 2040, the International Agency for Research on Cancer (IARC) projects that there will be 16.3 million cancer-related deaths and 27.5 million new cases worldwide. One of the main causes of disseminated intravascular coagulation (DIC) is cancer. Blood clotting proteins become overactive in a dangerous disorder known as diffused intravascular coagulation (DIC).
By purpose, clinical use segment is expected to continue leading the market over a CAGR of 6.0% throughout the projected timeframe. Coagulation tests have been shown to be clinically useful in the detection of cardiovascular illnesses and coagulation disorders, particularly DVT. Coagulant levels in the circulation increase dramatically in response to various illnesses, making it an important indicator for diagnosis. Because of their diagnostic usefulness, Coagulation tests are now widely used in clinical practice to guide antibiotic treatment and help clinical decision-making.
The hospitals have led the coagulation markers market as the leading end user with the CAGR of 7.4% in 2023 to 2033. Hospitals are the principal providers of acute care, serving a diverse variety of patients, including those suffering from severe chronic illnesses, coagulation problems, and other urgent circumstances. Coagulation tests are extremely useful in these conditions, assisting in the diagnosis, monitoring, and treatment of cardiovascular disorders. In these acute care circumstances, hospitals rely on coagulation tests to assist clinical decision-making, guide antibiotic treatment, and assess patient prognosis.
The coagulation markers industry is highly competitive, with numerous players vying for market share. In such a scenario, key players must adopt effective strategies to stay ahead of the competition.
Key Strategies Adopted by the Players
Companies invest heavily in research and development to deliver novel products that improve efficiency, dependability, and cost-effectiveness. Product innovation allows businesses to differentiate themselves from their competition while also catering to the changing demands of their clients.
Key industry leaders frequently develop strategic partnerships and collaborations with other companies in order to harness their strengths and increase their market reach. Companies might also gain access to new technology and markets through such agreements.
The coagulation markers sector is expanding rapidly in emerging regions such as China and India. Key firms are enhancing their distribution networks and developing local manufacturing facilities to increase their presence in these areas.
Mergers and acquisitions are frequently used by key players in the coagulation markers business to consolidate their market position, increase their product portfolio, and gain access to new markets.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Key Developments in the Coagulation Markers Market:
China, India, Japan dominate the market in Asia Pacific.
The healthcare sector is the main consumer of coagulation indicators.
The United States is predicted to record a CAGR of 5% from 2023 to 2033.
The global coagulation markers market was valued at US$ 1.21 billion in 2023
The global coagulation markers market is projected to reach US$ 2.22 billion by 2033.
Explore Healthcare Insights
View Reports